drugset / Trial / NCT00562497

Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)

NCT00562497

Phase 3 Completed 192 enrolled Mesoblast, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of Prochymal® versus placebo in combination with corticosteroids as initial therapy for acute GVHD. Corticosteroids have been the primary therapy for patients with previously untreated acute GVHD and the historical published data define an expected 35% complete response (CR) at Day +28 using this therapy.

Timeline

Start
2008-01-31
Primary completion
2009-07-14
Completion
2010-05-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prochymal® Cell therapy 2e+06 cells/kg Intravenous